NeuroVectis
Autologous Tissue-Engineered Therapy for Parkinson’s Disease
Company Overview
Snapshot
Founded in January 2026, NeuroVectis operates with 1–10 employees. The company is a planned Matricelf subsidiary focused on developing a regenerative therapy for Parkinson’s disease and Parkinsonism. In February 2026, Matricelf launched NeuroVectis as a spin-off to develop living brain implants.
Business overview
NeuroVectis is developing an autologous tissue-engineered therapy for Parkinson’s disease and Parkinsonism. The company's core technology involves using patient-derived cells, extracellular matrix, hydrogel, and engineered neural tissue to create a living implant. This implant is designed to restore dopamine production and support brain-tissue repair, aiming to provide a regenerative solution rather than merely managing symptoms. NeuroVectis operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.
Strategic signal
In February 2026, Matricelf launched NeuroVectis as a spin-off to develop living brain implants for Parkinson's disease. This strategic move signals a significant advancement in the pursuit of regenerative therapies for neurodegenerative conditions, indicating a focused effort to bring a novel, potentially curative treatment to market. For investors, this highlights a commitment to addressing a high-unmet medical need with an innovative, tissue-engineered approach.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuroVectis's primary focus?
- NeuroVectis is focused on developing an autologous tissue-engineered therapy for Parkinson’s disease and Parkinsonism, aiming to restore dopamine production and support brain tissue repair.
- When was NeuroVectis founded?
- NeuroVectis was founded in January 2026.
- What is the core technology behind NeuroVectis's therapy?
- The core technology involves creating a living implant using patient-derived cells, extracellular matrix, hydrogel, and engineered neural tissue.
- What was a significant recent development for NeuroVectis?
- In February 2026, Matricelf launched NeuroVectis as a subsidiary dedicated to developing and commercializing a medical solution for Parkinson's disease.
- What is the strategic goal of NeuroVectis's treatment?
- NeuroVectis aims to provide a regenerative therapy that not only manages symptoms but also restores dopamine production and supports brain tissue repair in Parkinson's patients.